Powered by 
Google Übersetzer
Google Übersetzer
Corbion Q3 2025 Interim Management Statement
Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through application of science, today publishes its results for the first nine months of 2025.
Key highlights first nine months 2025:
Organic sales growth: | +1.2% | (Q3: -2.2%) |
- Volume/mix: | +1.7% | (Q3: -1.5%) |
- Price: | -0.5% | (Q3: -0.7%) |
Sales | € 957.2 million | (Q3: € 311.6 million) |
Adjusted EBITDA | € 156.3 million | (Q3: € 49.7 million) |
Adjusted EBITDA organic growth | +22.9% |
|
Operating profit € 91.4 million, an organic increase of +59.6% | ||
Continued positive volume/mix development in Functional Ingredients & Solutions | ||
Volume/mix result in Health & Nutrition as indicated given high prior-year comparable | ||
FY 2025 outlook maintained | ||
€ million* | YTD 2025 | YTD 2024 | YTD growth | YTD |
| Q3 2025 | Q3 2024 | Q3 growth | Q3 |
Sales | 957.2 | 972.9 | -1.6% | +1.2% |
| 311.6 | 335.8 | -7.2% | -2.2% |
Adjusted EBITDA | 156.3 | 135.7 | +15.2% | +22.9% |
| 49.7 | 49.6 | +0.2% | +11.9% |
Adjusted EBITDA margin (%) | 16.3% | 13.9% | +240bps |
|
| 15.9% | 14.8% | +110bps |
|
Operating profit | 91.4 | 62.1 | 47.2% | +59.6% |
| 27.9 | 28.5 | -2.1% | +11.6% |
*Continued operations
Commenting on today’s results, Olivier Rigaud, CEO, stated: “We achieved solid results in the first nine months of 2025, reflecting the fundamental strength of our businesses. Q3 volume/mix results were in line with previously provided indications against the high comparable results in Q3 2024 for both segments. Adjusted EBITDA margins increased, both in YTD and Q3 terms by +240bps and +110bps, respectively. Thanks to strong progress in our cost-reduction initiatives and lower prices for some key inputs, along with our continued emphasis on operational efficiency, we've achieved higher YTD margins in both segments.
The Functional Ingredients & Solutions segment maintained sales momentum driven both in YTD and Q3 results. As anticipated, pricing was slightly down for the segment mainly attributable to the pass-through pricing mechanism in Lactic acid to the PLA joint venture.
In Health & Nutrition, we delivered excellent growth in Adjusted EBITDA despite the decline in volume/mix in the quarter, mainly due to the high comparable in Q3 2024— particularly in the Nutrition business’s sales to aquaculture. The Pharma business showed positive sales growth due to increased volume/mix in year-to-date and Q3. Strong volume/mix growth in Health & Nutrition is anticipated in Q4, more than compensating for the Q3 decline.
Based on the strong YTD results published today, we maintain our full-year 2025 guidance. Based on the visibility into our current orderbook in Q4, we expect volume/mix growth to be in the range of +3-5%.
Attachment
